AstraZeneca is pioneering novel cell therapies for some of the world’s most common chronic diseases

Natasha Cowan, Senior Corporate Communications Manager | May 09, 2023

Hero image

We sat down with Professor Francesco Dazzi, Medical Lead Cell Therapy, BioPharmaceuticals R&D at AstraZeneca, to learn about the company’s groundbreaking cell therapy pipeline in cardiovascular, renal, and metabolic diseases and in immunology and discuss why developing cell therapy for a large patient population requires a different approach.

During the last five years, we have witnessed an explosion in cell therapy innovation. Significant advances in the understanding of disease biology and major innovations in gene editing, protein engineering, and cell culture technology have created a highly fertile scientific environment in which cell therapy research is flourishing. As an early innovator in cell therapy, AstraZeneca BioPharmaceuticals is now investigating the potential of this exciting technology across cardiovascular, renal, and metabolic diseases and immunological diseases.

This represents a paradigm shift for cell therapy. Across the industry, much of the research in this area has concentrated on developing treatments for complex cancers and rare diseases, which generally target small patient populations. AstraZeneca is developing potential groundbreaking treatments for some of the most prevalent diseases in the world. Not only is it meeting significant unmet need, but it also is breaking new ground in these disease areas.

Leveraging its cross-functional expertise from oncology, the company is exploring the removal of disease-causing or dysfunctional cells using engineered immune cells, such as CAR-T cells. Its innovative pipeline includes engineering Treg cells, which act as “natural brakes” in the immune system and control the activity of other immune cells. These Treg cells are engineered using CRISPR gene-editing technology with the aim to treat inflammatory diseases. Using functional genomic screens, its scientists are identifying potential targets that they want to engineer in the cells. The company is also exploring a next-generation off-the-shelf CAR-T therapy for immunological diseases.

 

Learn more about the company’s cell therapy pipeline and challenges from Francesco Dazzi, Medical Lead Cell Therapy, BioPharmaceuticals R&D at AstraZeneca.

Latest articles

Amar Urhekar joins Fishawack Health as Chief Operating Officer, integrating interdisciplinary teams across capabilities

September 12, 2023

Avoid the narrow framing trap—Take a more empathetic approach to medication adherence

August 23, 2023

Fishawack Health amplifies US Marketing leadership team with appointment of Celine Vita as Chief Growth Officer

August 10, 2023

How we use cookies

Cookies are files saved on your phone, tablet or computer when you visit a website.

We use cookies to store information about how you use the Fishawack Health website, such as the pages you visit.

For more information, check the cookie statement

Cookie settings

We use 4 types of cookies. You can choose which cookies you're happy for us to use.

Cookies that measure website use

We use Google Analytics to measure how you use the website so we can improve it based on user needs. We do not allow Google to use or share the data about how you use this site.

  • how you got to the site
  • the pages you visit on fishawack.com, and how long you spend on each page
  • what you click on while you're visiting the site

Cookies that help with our communications and marketing

These cookies may be set by third party websites and do things like measure how you view Vimeo videos that are on Fishawack.com.

Cookies that remember your settings

These cookies do things like remember your preferences and the choices you make, to personalize your experience of using the site.

Strictly necessary cookies

These essential cookies do things like remember your progress through a form (eg. Registering for new content alerts).

These cookies always need to be on.